Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema …

NEW YORK–(BUSINESS WIRE)–Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that results from its Phase 2 trial of CIRARA™ for preventing edema (brain swelling) in large hemispheric infarctions will be presented during two oral presentations at the 68th annual American Academy of Neurology (AAN) meeting, the world’s largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe. This year’s weeklong meeting will take place April 15-21 in Vancouver, BC. The two oral presentations will be conducted by principal investigators and leading neuroscience researchers at Yale University and Massachusetts General Hospital. Details for the two oral presentations include: Session Title: Stroke Clinical TrialsTitle of Talk: GAMES (Glyburide Advantage in…


Link to Full Article: Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema …